OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events

Published

May 10, 2024

OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events

Oxford, United Kingdom – 10th May 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, is pleased to confirm that it will be presenting and attending a number of upcoming conferences, as detailed below.

 

  • BioEquity Europe 2024, May 12-14, San Sebastian – Rosamond Deegan, CEO of OMass; Ali Jazayeri, CSO of OMass
    • Corporate presentation on May 13 at 12:15

 

 

 

Rosamond Deegan, CEO of OMass of OMass said: “We have made great strides across our portfolio, including our MC2 antagonist, and are excited to share this progress at various business and scientific meetings.”

 

If you would like to meet with any of the OMass team during these events or at any other time, please contact miguel.silva@omass.com.

 

-ENDS-

For further information, please contact:

OMass Therapeutics ICR Consilium
Rosamond Deegan, Chief Executive Officer

Phone: +44 (0)1235 527589

Email: ros.deegan@omass.com

 

Sue Charles / Suki Virji / Kumail Waljee

Phone: +44 (0)20 3709 5700

Email: omass@consilium-comms.com

 

About OMass Therapeutics

OMass Therapeutics is a biotechnology company discovering medicines against highly- validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. This allows OMass to interrogate not just the target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs.

Headquartered in Oxford, UK, OMass has raised over $160M (£129M) from a top-tier international investor syndicate, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.

To learn more, please visit www.omass.com. Follow us on LinkedIn and Twitter.

MORERelated News
OMass Therapeutics Announces its Attendance at Upcoming Conferences and Events
Oxford, United Kingdom – 10th May 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...
OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer
Oxford, United Kingdom – 15 November 2023 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against...